1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Early Data On Amgen’s AMG 133 Show Potential Durability, Dosing Advantage In Obesity

 
• By Alaric DeArment

The drug is dosed once every four weeks – compared with Mounjaro and Wegovy’s weekly dosing – but the company also signaled it is considering extended dosing intervals.

Amgen announced data on AMG 133 in obesity • Source: Shutterstock

It’s still early days, but the first set of data on Amgen, Inc.’s bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule, AMG 133, suggest it could gain an advantage on the market with its efficacy, durability and less frequent dosing in treating obesity than competing drugs.

Amgen presented data for AMG 133 on 3 December at the World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Clinical Trials

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By Joseph Haas

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win

 
• By Alaric DeArment

The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 
• By Andrew McConaghie

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By Kevin Grogan

Comes Days After PDUFA Pushback For GSK's Blenrep.

More from R&D

Pipeline Watch: Twelve Approvals And Six Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 
• By Jessica Merrill

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.